Last reviewed · How we verify

Hydroxycarbamide Tablets — Competitive Intelligence Brief

Hydroxycarbamide Tablets (Hydroxycarbamide Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ribonucleotide reductase inhibitor. Area: Oncology; Hematology.

phase 3 Ribonucleotide reductase inhibitor Ribonucleotide reductase Oncology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxycarbamide Tablets (Hydroxycarbamide Tablets) — Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hydroxycarbamide Tablets TARGET Hydroxycarbamide Tablets Suzhou Zelgen Biopharmaceuticals Co.,Ltd phase 3 Ribonucleotide reductase inhibitor Ribonucleotide reductase
Gemzar Gemcitabine Hydrochloride Accord Hlthcare marketed Nucleoside metabolic inhibitor Ribonucleotide reductase; DNA incorporation 1996-01-01
HYDROXYUREA HYDROXYUREA marketed Antimetabolite [EPC] Ribonucleotide reductase 1967-01-01
Hydrea® (hydroxyurea ) Hydrea® (hydroxyurea ) Assistance Publique - Hôpitaux de Paris marketed Antimetabolite; ribonucleotide reductase inhibitor Ribonucleotide reductase
Fludarabine (FLU) Fludarabine (FLU) Nanfang Hospital, Southern Medical University marketed Purine nucleoside analog Ribonucleotide reductase, DNA polymerase
Fludarabine (Flud) Fludarabine (Flud) Technische Universität Dresden marketed Purine analog antimetabolite Ribonucleotide reductase, DNA polymerase
Platinum + Gemcitabine Platinum + Gemcitabine Fondazione Policlinico Universitario Agostino Gemelli IRCCS marketed Chemotherapy combination (platinum agent + nucleoside analog) DNA (platinum crosslinking); ribonucleotide reductase and DNA polymerase (gemcitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Ribonucleotide reductase inhibitor class)

  1. Vanderbilt University Medical Center · 4 drugs in this class
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  3. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxycarbamide Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxycarbamide-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: